Gotham City Capital
Healthcare, biotech, mid-cap, small-cap

Previous Data Signals Positive Phase IIb Results Likely To Come For Synergy Pharmaceuticals

Written by Travis Knight

All eyes are once again on Synergy Pharmaceuticals (NASDAQ:SGYP) in anticipation of Phase IIb data to be released regarding its 350-patient study, evaluating patients with IBS-C (irritable bowel syndrome with constipation). The company expects completion of the study by April, with topline Phase IIb data to follow shortly afterwards. In December, enrollment was closed for this study and the company guided that data would be released at the beginning of the second quarter, a bit later than initially guided. A sell-off in share price following the news has given investors the opportunity to grab shares at a really good price. With increasing confidence in plecanatide based on previous data studying patients with a...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
PRO Top long ideas returned 21.7% in 2016**
"As a PRO member, we get uniquely valuable perspective that go beyond our quantiative analysis... We rely on PRO to get beyond the numbers quickly and add much needed perspective. It keeps me ahead of the next big thing. - Mark Choate, Malaga Cove Capital"
Mark Choate, Malaga Cove Capital
"Contributors (writers and commentators), often have a long history in the secuirities they opine on and some are clearly well positioned industry participants with detailed industry views that can help provide color on where the skeletons are buried in a particular secuirity and/or industry."
Jim Roumell, Roumell Asset Management
Annual subscriptions may be cancelled for any reason within the first 30 days and receive a full and prompt refund. Details